{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:16:33Z","timestamp":1777482993579,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the clinical efficacy of febuxostat combined with a low\u2010purine diet versus allopurinol combined with a low\u2010purine diet in the treatment of gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<jats:bold>s<\/jats:bold><\/jats:title><jats:p>In this prospective controlled trial, 98 gout patients admitted to our hospital from February 2021 to December 2022 were enrolled as study subjects. Patients were randomly assigned to the study group (febuxostat combined with a low\u2010purine diet) and the control group (allopurinol combined with a low\u2010purine diet), with 49 patients in each group. The therapeutic effect was evaluated based on joint function and serum uric acid levels after treatment, and classified into three levels: markedly effective, effective, and ineffective. The levels of inflammatory factors, including tumor necrosis factor\u2010a (TNF\u2010a), cytokine interleukin\u20101beta (IL\u20101\u03b2), and interleukin (IL)\u201018 (IL\u201018), were collected. The Numeric Rating Scale (NRS) was used to assess the degree of pain in patients. Clinical indicators before and 6\u2009months after treatment were compared between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no statistically significant difference in age and gender between the two groups. After 6\u2009months of treatment, the effective rate in the study group (48 cases, 97.96%) was higher than that in the control group (42 cases, 85.71%), with a statistically significant difference (<jats:italic>p<\/jats:italic>\u2009=\u2009.027). At the same time, the study group had significantly lower levels of serum uric acid (162.39\u2009\u03bcmol\/L\u2009\u00b1\u200917.23\u2009\u03bcmol\/L vs. S198.32\u2009\u03bcmol\/L\u2009\u00b1\u200918.34\u2009\u03bcmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), creatinine (87.39\u2009mmol\/L\u2009\u00b1\u20099.76\u2009mmol\/L vs. 92.18\u2009mmol\/L\u2009\u00b1\u20099.27\u2009mmol\/L, <jats:italic>p<\/jats:italic>\u2009=\u2009.014), total cholesterol (3.65\u2009mmol\/L\u2009\u00b1\u20090.65\u2009mmol\/L vs. 4.76\u2009mmol\/L\u2009\u00b1\u20090.73\u2009mmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001), and triglycerides (1.76\u2009mmol\/L\u2009\u00b1\u20090.32\u2009mmol\/L vs. 2.28\u2009mmol\/L\u2009\u00b1\u20090.41\u2009mmol\/L, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) compared to the control group, with statistically significant differences (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). After treatment, the levels of inflammatory factors and degree of pain in the study group were significantly lower than those in the control group (all <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). During the treatment process, the incidence of adverse reactions in the study group (2 cases, 4.08%) was lower than that in the control group (9 cases, 18.37%), with a statistically significant difference (<jats:italic>p<\/jats:italic>\u2009=\u2009.025).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Febuxostat combined with a low\u2010purine diet can reduce inflammatory factors and alleviate the degree of pain in gout patients, significantly improving their clinical symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.15165","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:28:32Z","timestamp":1716272912000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the therapeutic effects of febuxostat combined with a low\u2010purine diet and allopurinol combined with a low\u2010purine diet on the improvement of gout patients"],"prefix":"10.1111","volume":"27","author":[{"given":"Xuejiao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Affairs Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Data Center Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2995-5435","authenticated-orcid":false,"given":"Na","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Affiliated Hospital of Hebei Engineering University  Handan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2018.10.012"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215315"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14173525"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12833"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.410"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063188"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01020-y"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2022.04.003"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0149-7"},{"issue":"4","key":"e_1_2_14_13_1","first-page":"1234","article-title":"A comprehensive review on gout: the epidemiological trends, pathophysiology, clinical presentation, diagnosis and treatment","volume":"71","author":"Ashiq K","year":"2021","journal-title":"J Pak Med Assoc"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23643"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211062770"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0115-y"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05079-3"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"issue":"3","key":"e_1_2_14_21_1","first-page":"181","article-title":"Guideline for the diagnosis and management of hyperuricemia and gout in China(2019)","volume":"35","author":"Chinese Society of Endocrinology","year":"2019","journal-title":"Chin J Endocrinol Metab"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.06.013"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001126"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000573"},{"issue":"4","key":"e_1_2_14_26_1","first-page":"1623","article-title":"The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia","volume":"31","author":"Wang S","year":"2018","journal-title":"Pak J Pharm Sci"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S357159"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000284"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.0698"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.15165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:11:14Z","timestamp":1716797474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.15165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/1756-185X.15165"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.15165","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2024-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15165"}}